Neurofibrillary tangles (NFTs) are a hallmark of Alzheimer’s disease, formed by the accumulation of tau protein into ...

Two new PET radiotracers have outperformed the only current Food and Drug Administration (FDA) approved radiotracer for detecting tau tangles in the brain, a hallmark of Alzheimer's disease. In a head ...

New serine biomarkers show promise for early Alzheimer's detection, linking tau assemblies to cognitive decline and offering ...

A new biomarker test identifies very early stages of tau tangle formation, up to a decade before any tau clumps can show up ...

(HealthDay News) — Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the Alzheimer’s Association and the Society for Nuclear Medicine ...

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the ...

Rabinovici et al, Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup, Alzheimer's ...

In pursuit of this vision, subsidiaries of Enigma have provided the best-in-class Tau and Amyloid PET imaging biomarkers, MK-6240 and NAV-4694, to our partners to enable their research efforts.

Lantheus' oncology portfolio includes Pylarify (piflufolastat F 18) and a growing pipeline addressing various solid tumours.

By quantifying the amount of tau in the brain tissue with PET imaging, physicians can appropriately stage Alzheimer’s disease in patients and determine the best treatment options. “Identifying ...

By quantifying the amount of tau in the brain tissue with PET imaging, physicians can appropriately stage Alzheimer's disease in patients and determine the best treatment options. "Identifying tau ...